Alectinib drug handling study for ALK-positive advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old (any sex)
- Have NSCLC confirmed by biopsy and ALK gene rearrangement found by an FDA-approved test (IHC or FISH)
- Have stage IIIB to IV lung cancer that has come back, or progressed (recurrent disease)
- Have had an ALK-targeting medicine as first treatment, plus one prior chemotherapy line with platinum
- Have measurable disease and good overall body strength (Karnofsky score 70 or higher)
- Have adequate blood, liver, and kidney function, and expected survival of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Hear when a new NSCLC Stage IIIB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.